目的：评价奥卡西平治疗原发性三叉神经痛的临床疗效及对患者睡眠质量的改善作用。方法将120例原发性三叉神经痛患者随机分为两组，各60例。治疗组采用奥卡西平治疗，对照组采用卡马西平治疗，治疗12周。对患者疼痛视觉模拟评分( VAS )、匹兹堡睡眠指数（PSQI）、不良反应发生率进行评估。结果治疗12周后，治疗组总有效率为88.33%，明显高于对照组的76.67%( P＜0.05)；两组患者睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、催眠药物、日间活动障碍，PSQI总分均较治疗前降低( P＜0.05)，但治疗组患者睡眠质量、入睡时间、睡眠时间、睡眠效率、日间活动障碍及 PSQI 总分改善优于对照组( P＜0.05)；治疗组不良反应发生率为8.33%，显著低于对照组的16.67%( P＜0.05)。结论奥卡西平作为治疗原发性三叉神经痛的一线用药，镇痛效果佳、临床疗效优、不良反应率低，且可有效改善患者睡眠质量，值得临床推广。%Objective To evaluate the clinical efficacy and sleep quality improvement of oxcarbazepine in treatment of primary trigeminal neuralgia ( PTN ) . Methods 120 patients with PTN were randomly divided into 2 groups, 60 cases in each group. The treatment group took oxcarbazepine, while the control group adopted the carbamzepine treatment. The VAS, PSQI scores and occurrence rate of adverse reactions after 12-week treatment were evaluated. Results The total effective rate in the treatment group was 88. 33%, which was sig-nificantly higher than 76. 67% in the control group ( P < 0. 05 ); the sleep quality, falling asleep time, sleep efficiency, sleep disorder, hypnotic drugs, days activity disorder and PSQI scores in the two groups were decreased compared with before treatment ( P < 0. 05 );but the effects of the treatment group in the aspects of sleep quality, falling asleep time, sleep time, sleep efficiency, days activity disorder and PSQI scores were superior to the control group ( P < 0. 05 ); the occurrence rate of adverse reactions in the treatment group was 8. 33%, which was significantly lower than 16. 67% in the control group with statistical difference ( P < 0. 05 ) . Conclusion Oxcar-bazepine as the first line drug for treating PTN has good analgesic effect, excellent clinical efficacy and low occurrence rate of adverse reactions, moreover can effectively improve the sleep quality and is worthy of being popularized in clinic.
展开▼
